Related Experiment Video
Updated: Dec 20, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer
Amila Suraweera1,2, Alex Duff3, Mark N Adams3,4
1Queensland University of Technology (QUT), School of Biomedical Sciences, Institute of Health and Biomedical Innovation and Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia. amila.suraweera@qut.edu.au.
Background:
Non-small cell lung cancers (NSCLC) account for 85-90% of all lung cancers. As drug resistance critically impairs chemotherapy effectiveness, there is great need to identify new therapeutic targets. The aims of this study were to investigate the prognostic and therapeutic potential of the copper-metabolism-domain-protein, COMMD4, in NSCLC.
Methods:
The expression of COMMD4 in NSCLC was investigated using bioinformatic analysis, immunoblotting of immortalised human bronchial epithelial (HBEC) and NSCLC cell lines, qRT-PCR and immunohistochemistry of tissue microarrays. COMMD4 function was additionally investigated in HBEC and NSCLC cells depleted of COMMD4, using small interfering RNA sequences.
Results:
Bioinformatic analysis and in vitro analysis of COMMD4 transcripts showed that COMMD4 levels were upregulated in NSCLC and elevated COMMD4 was associated with poor prognosis in adenocarcinoma (ADC). Immunoblotting demonstrated that COMMD4 expression was upregulated in NSCLC cells and siRNA-depletion of COMMD4, decreased cell proliferation and reduced cell viability. Cell death was further enhanced after exposure to DNA damaging agents. COMMD4 depletion caused NSCLC cells to undergo mitotic catastrophe and apoptosis.
Conclusions:
Our data indicate that COMMD4 may function as a prognostic factor in ADC NSCLC. Additionally, COMMD4 is a potential therapeutic target for NSCLC, as its depletion induces cancer cell death.
Insights
COMMD4 is upregulated in non-small cell lung cancer (NSCLC) and linked to poor prognosis. Depleting COMMD4 in NSCLC cells halts proliferation and induces cancer cell death, suggesting it as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) is the most common form of lung cancer.
- Drug resistance in NSCLC necessitates novel therapeutic targets.
- COMMD4 (copper-metabolism-domain-protein) is investigated for its role in NSCLC.
Purpose of the Study:
- To investigate the prognostic and therapeutic potential of COMMD4 in NSCLC.
- To determine if COMMD4 expression correlates with patient outcomes.
- To explore COMMD4 as a potential drug target for NSCLC treatment.
Main Methods:
- Bioinformatic analysis of COMMD4 expression in NSCLC.
- Immunoblotting, qRT-PCR, and immunohistochemistry to assess COMMD4 levels.
- Functional studies using siRNA to deplete COMMD4 in NSCLC and bronchial epithelial cells.
Main Results:
- COMMD4 expression is upregulated in NSCLC and associated with poor prognosis in adenocarcinoma.
- COMMD4 depletion reduces NSCLC cell proliferation and viability.
- COMMD4 inhibition induces mitotic catastrophe and apoptosis in NSCLC cells, especially when combined with DNA damaging agents.
Conclusions:
- COMMD4 serves as a prognostic factor in adenocarcinoma NSCLC.
- COMMD4 is a potential therapeutic target for NSCLC.
- Targeting COMMD4 can induce cancer cell death, offering a new treatment strategy.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...